Eyeworld

I prescribe IYUZEH because it has no preservatives, and the data clearly showed that it lowered IOP at rates comparable to XALATAN ® . That makes IYUZEH a go-to treatment for my patients. Jason M. Bacharach, MD Dr. Bacharach is a paid consultant of Thea Pharma Inc. IYUZEH is a trademark of Laboratoires Théa. Copyright ©2024 Thea Pharma Inc. | All Rights Reserved. | PRC-IYZ-1954-v1 03.2024 INDICATIONS AND USAGE IYUZEH™ (latanoprost ophthalmic solution) 0.005% is a prostaglandin F2α analogue indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS Known hypersensitivity to latanoprost or any other ingredients in this product. WARNINGS AND PRECAUTIONS IYUZEH may cause changes to pigmented tissues. Most frequently reported changes are increased pigmentation of the iris, periorbital tissue (eyelid), and eyelashes. Pigmentation is expected to increase as long as IYUZEH is administered. Iris pigmentation is likely to be permanent. Eyelid skin darkening and eyelash changes may be reversible. IYUZEH may cause gradual change to eyelashes including increased length, thickness, and number of lashes. These changes are usually reversible upon discontinuation of treatment. IYUZEH should be used with caution in patients with a history of intraocular infl ammation (iritis/uveitis) and should generally not be used in patients with active intraocular infl ammation. IYUZEH should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema. Reactivation of herpes simplex keratitis has been reported during treatment with latanoprost. IYUZEH should be used with caution in patients with a history of herpetic keratitis. Contact lenses should be removed prior to the administration of IYUZEH and may be reinserted 15 minutes after administration. ADVERSE REACTIONS The most common adverse reactions (5% to 35%) for IYUZEH are: conjunctival hyperemia, eye irritation, eye pruritus, abnormal sensation in eye, foreign body sensation in eyes, vision blurred, and lacrimation increased. DRUG INTERACTIONS The combined use of two or more prostaglandins or prostaglandin analogs including IYUZEH is not recommended. It has been shown that administration of these prostaglandin drug products more than once daily may decrease the IOP lowering effect or cause paradoxical elevations in IOP. Please see full Prescribing Information at www.iyuzeh.com and Brief Summary on the next page. Explore the power of preser vative -free latanoprost at iyuzeh.com IYUZEH ™ (latanoprost ophthalmic solution) 0.005% is the fi rst and only preservative-free latanoprost for patients with open-angle glaucoma (OAG) and ocular hypertension (OHT). XALATAN is a registered trademark of Pfi zer PFE Holdings 4 LLC, a Viatris Company.

• Cover